Affymax Announces Decision in Arbitration Against JNJ

Affymax, Inc. AFFY today announced that it has received a decision from the arbitration panel reviewing its dispute against certain subsidiaries of Johnson and Johnson JNJ. The panel has determined that Affymax and JNJ are co-owners of certain intellectual property, including U.S. patent numbers 5,773,569, 5,830,851, 5,986,047, among others related to erythropoietin receptor agonists. In addition, the ruling determined that JNJ is sole owner of JNJ's U.S. patent number 5,767,078 (‘078) and certain other related patents and patent applications in Europe, Japan, Canada and Australia.